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Abstract 
MeDALL (Mechanisms of the Development of ALLergy; EU FP7-CP-IP; Project No: 261357; 2010-
2015) proposed an innovative approach to develop early indicators for the prediction, diagnosis, 
prevention and targets for therapy. MeDALL linked epidemiological, clinical and basic research using 
a stepwise, large-scale and integrative approach: precisely phenotyped children followed in 14 birth 
cohorts spread across Europe were combined with systems biology (omics, IgE measurement using 
micro-arrays) and environmental data. Multimorbidity in the same child is more common than 
expected by chance alone, suggesting that these diseases share causal mechanisms irrespective of IgE 
sensitisation. IgE sensitisation should be considered differently in mono and polysensitized 
individuals. Allergic multimorbidities and IgE polysensitization are often associated with the 
persistence or severity of allergic diseases. Environmental exposures are relevant for the development 
of allergy-related diseases. To complement the population-based studies in children, MeDALL 
included mechanistic experimental animal studies and in vitro studies in humans. The integration of 
multimorbidities and polysensitization has resulted in a new classification framework of allergic 
diseases that could help to improve the understanding of genetic and epigenetic mechanisms of allergy 
as well as to better manage allergic diseases. Ethics and gender were considered. MeDALL had 
translational activities deployed within the EU agenda. 
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AD: atopic dermatitis 
AMIC: Asthma Multicentre Infant Cohort Study 
AIRWAYS ICPs: Integrated care pathways for airway diseases (EIP on AHA) 
BAMSE – Barn Allergi Milj. Stockholm Epidemiologi Projektet    
BIB: Born in Bradford 
CC16: club cell secretory protein 
CQ: Core Questionnaire 
DARC: Danish Allergy Research Centre   
ECA: Environment and Childhood Asthma  
ECRHS: European Community Respiratory Health Survey   
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EIP on AHA: European Innovation Partnership on Active and Healthy Ageing 
EGEA: Epidemiological study on the Genetics and Environment of Asthma, bronchial hyperresponsiveness and atopy 
EFA: European Federation of Allergy and Airways Diseases Patients' Associations 
ENRIECO- Environmental Health Risks in European Birth Cohorts 
ESCAPE: European Study of Cohorts for Air Pollution Effects 
EU: European Union 
GA2LEN: Global Allergy and Asthma European Network 
GARD: WHO Global Alliance against Chronic Respiratory Diseases 
GINIplus: German Infant study on the influence of Nutrition Intervention PLUS environmental and genetic influences on 
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HDM: House dust mite  
IgE: Immunoglobulin E 
INMA: Infancia y medio ambiente 
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the influence of traffic emissions and genetics mAb: monoclonal antibody 
MAAS: Manchester Asthma and Allergy Study 
MAS: German Multicenter Allergy Study 
MeDALL: Mechanisms of the Development of ALLergy 
MHC: major histocompatibility complex 
NCD: Noncommunicable disease 
PARIS: Pollution and Asthma Risk: an Infant Study 
PIAMA: The Prevention and Incidence of Asthma and Mite Allergy  
RHEA: Mother-Child cohort in Crete 
Robbic: Rome and Bologna birth cohorts 
SPT: skin prick test 
TCR: T cell receptor 
Treg: T regulatory cell 
WAO: World Allergy Organization 
 
Introduction 
Allergic diseases such as asthma, rhinitis and eczema are complex and associated with allergen-
specific IgE and non-allergic mechanisms (1). They often coexist in the same subject (multimorbidity) 
(2) and are multifactorial, with genetic, life-style and environmental components. These interactions 
start early in life, develop during infancy and childhood (3), and may persist throughout life.  
Allergic diseases are not separate diseases but are linked by complex and insufficiently defined inter-
relationships across the life cycle. There is a growing interest to apply the systems approach proposed 
in systems biology to complex chronic diseases (4).  The 7th Framework Programme of the EU 
promoted research to develop systems medicine in order to better understand chronic diseases.  
MeDALL (Mechanisms of the Development of ALLergy; EU FP7-CP-IP; Project No: 261357; 2010-
2015) attempted to better understand the complex links of allergic diseases at the clinical and 
mechanistic levels (1, 5).  
MeDALL completed its project in May 2015 and the present paper reports the results and 
achievements published by the consortium to date. 
 
1- Innovative approach 
MeDALL was one of the first EU projects to adopt a systems medicine approach for the understanding 
of complex NCDs (1, 5). It has generated novel knowledge on the mechanisms of initiation of allergy 
from early childhood to young adulthood. MeDALL has linked epidemiological, clinical and basic 
research (6). It was based on a novel, stepwise, large-scale and integrative approach led by a network 
of all necessary experts. The following steps were proposed and developed during the project:  
1- Identification of “classical” and “novel” phenotypes in existing birth cohorts (Table 1).  
2- Discovery of the relevant mechanisms in IgE-associated allergic diseases in existing longitudinal 
birth cohorts. 
3- Validation and redefinition of the classical and novel phenotypes of IgE-associated allergic 
diseases.  
4- Translational integration of systems biology outcomes into healthcare, including societal aspects. 
 
Table 1: MeDALL dual approach 
Hypothesis-driven approach: The identification of classical phenotypes was based on experts’ criteria following 
a review of the literature aiming at the definition of IgE-associated allergic diseases.  
Data-driven approach: To identify the novel phenotypes, the children from the birth cohorts were analysed 
using hypothesis-free methods by cluster analysis. 
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The strategy of MeDALL was based on information and samples (already existing in the repository 
and acquired during the project) obtained from a large network of 14 ongoing birth cohorts.   
 
2- Major methodological achievements 
2-1- Development of a knowledge management platform.   
Systems medicine involves the large scale integration of existing knowledge with newly acquired 
multidimensional data. The MeDALL knowledge management platform was developed to empower 
all partners with open sharing and access to all the data and information collected, as well as all the 
experimental and computational procedures. The MeDALL knowledge base integrates historical and 
newly collected data from around 44,000 participants on 398 clinical and phenotypic attributes 
(harmonised from 7,495 individual cohort variables) and 160 different follow-ups at 25 different time-
points between pregnancy and age 20 as well as information about available blood samples. Samples 
are stored in the individual biobanks of the different MeDALL partners.  
Information on 863 genes involved in allergy (283 from a systematic literature review, 580 from 
automatic text mining) is integrated with data on protein-protein interactions, transcriptional 
regulation, miRNA regulation and signalling pathways from public databases. It is directly connected 
to the omics data generated within MeDALL.  
Omics data produced or made available within MeDALL includes 23,000 historical GWAS, 9,500 
epigenetics, 2,000 proteomics, 750 transcriptomics, IgE micro-arrays (4,000 subjects) and individual 
estimates of ambient air pollution exposure (10,000 children) using the land use model (ESCAPE) (7-
10).  
The newly performed epigenetics, proteomics, transcriptomics and IgE micro-array data are integrated 
into the MeDALL knowledge base which currently includes 3,292 IgE-chips, 2,173 DNA-
methylations, 1,427 biomarkers and 723 transcription experiments. The availability of longitudinal 
samples of the same individual is a unique resource. 
 
2-2- Development of the harmonised MeDALL-Core questionnaire (in 8 languages) (11) 
Numerous birth cohorts have been initiated throughout the world using heterogeneous methods to 
assess the incidence, course and risk factors of asthma and allergies (12). One of the major 
achievements of MeDALL was the development of the harmonized MeDALL-Core Questionnaire 
(MeDALL-CQ), used historically in 14 cohorts and prospectively in 11 (11). The harmonization of 
standardized core questions was accomplished in 4 steps: (i) collection of previous questions from 14 
European birth cohorts, (ii) consensus on core questionnaire items, (iii) translation and back-
translation of the harmonized English MeDALL-CQ into 8 other languages, and (iv) implementation 
of the 3 core questionnaires MeDALL-CQ (2 for parents of children aged 4-9 and 14-18, 1 for 
adolescents aged 14-18). The harmonized MeDALL follow-up leads to more comparable data across 
different cohorts and offers the possibility to validate the results of former single cohort analyses. 
Worldwide interest has been expressed in the MeDALL CQs: future follow-up assessments of the 
Cincinnati Childhood Allergy and Air Pollution Study (CCAAPS) birth cohort (13) and of the large 
Japanese national birth cohort Japan Environment and Children's Study (JECS), which recently 
recruited 100,000 parent-child pairs (www.env.go.jp/en/chemi/hs/jecs/).  
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2-3- Development of a database of pooled cohorts using a harmonized 
questionnaire (12)    
MeDALL birth cohorts include AMICS-Menorca** (14), BAMSE** (15), BIB* (16, 17), DARC** 
(18), ECA** (19), EDEN* (20), GINI plus** (21, 22), INMA* Gipuzkoa, Sabadell, Valencia (23), 
LISA plus** (24), MAS (25-28), PARIS* (29), PIAMA (30), RHEA*(31) and ROBIC* (32). 
MeDALL included the birth cohorts with historical databases and harmonised follow up (11)  
integrated in a knowledge management system (33) (Table 2).  
Table 2: Pooled MeDALL database 
 
• AMICS-M: data from 482  integrated participants with up to 12 follow-ups 
• BAMSE: data from 4,089 integrated participants with up to 5 follow-ups 
• BiB: data from 13,565 (2,594 in MeDALL) integrated participants with up to 7 follow-ups 
• DARC: data from 562 integrated participants with up to 9 follow-ups 
• ECA: data from 3,754 integrated participants with up to 6 follow-ups 
• EDEN: data from 1,140 integrated participants with up to 6 follow-ups 
• GINI: data from 5,991 integrated participants with up to 8 follow-ups  
• LISA: data from 3,095 integrated participants with up to 9 follow-ups  
• INMA-Gipuzkoa: data from 406 integrated participants with up to 4 follow-ups 
• INMA-Sabadell: data from 772 integrated participants with up to 7 follow-ups 
• INMA-Valencia: data from 855 integrated participants with up to 6 follow-ups 
• MAS: data from 1,314 integrated participants with up to 19 follow-ups 
• PARIS: data from 1,549 integrated participants with up to 10 follow-ups 
• PIAMA: data from 3,963 integrated participants with up to 12 follow-ups 
• RHEA: data from 1,336 integrated participants with up to 6 follow-ups 
• ROBBIC-Bologna: data from 434 integrated participants with up to 5 follow-ups 
• ROBBIC-Roma: data from 694 integrated participants with up to 6 follow-ups 
A joint NIH-MeDALL workshop on birth cohorts in allergy and asthma was organised in September 
2012 to address a wide research agenda, including potential new study designs and the harmonisation 
of existing birth cohort data (6).  
 
The MeDALL database with its new central database is the starting point for future common and 
sustainable research initiatives in asthma and allergy. It can be extended with other epidemiologic 
studies such as birth and patient cohorts.   
 
2-4- Development of a new allergen microarray technology  
The “MeDALL allergen-chip” is a collection of 170 allergen molecules for the reliable detection of 
allergen-specific antibody signatures showing a higher sensitivity than the traditional ImmunoCAP 
system and skin prick testing. This new tool has been integrated in clinical work within MeDALL and 
beyond, allowing a hitherto not available precision regarding the mapping of sensitization profiles 
down to the level of disease-causing allergens and the monitoring of the early evolution of the allergic 
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immune response (34-37). The MeDALL allergen-chip is a customized chip by Thermofisher which 
includes a large collection of allergens produced by the MeDALL consortium.   
 
2-5- Applying bioinformatics to develop the systems medicine approach 
The working hypothesis underlying systems medicine approaches is that biological function and 
dysfunction in disease develop from the interplay between spatial and temporal processes involving 
multiple components interacting in complex networks. The ultimate goal of systems medicine is 
therefore to understand, as fully as possible, this integrative process, and to identify directions to 
investigate the development of more efficient clinical diagnostics and therapies. In MeDALL, we have 
integrated bioinformatics with more traditional methods (classical and novel phenotypes). We have 
used machine learning methods as an unsupervised strategy to identify novel phenotypes and have 
developed an in silico model of multimorbidity.   
 
2-5-1 Applying machine learning methods to identify novel phenotypes 
In MeDALL, we used an unsupervised approach to identify novel phenotypes. At variance with 
previous studies that applied this method to one single disease, we assessed asthma, rhinitis and 
eczema together in the same models (5). We included 17,209 children at 4 years and 14,585 at 8 years 
from seven birth cohorts. At each age period, we performed partitioning cluster analysis, according to 
the distribution of 23 variables covering symptoms 'ever' and 'in the last 12 months', doctor diagnosis, 
age of onset and treatments of asthma, rhinitis and eczema; IgE sensitization; weight; and height. The 
analysis used repeated latent class analysis and self-organizing maps. 
 
2-5-2-  Development of a bioinformatic model of multimorbidity of  allergic diseases 
An in silico study based on computational analysis of the topology of the protein interaction network 
was performed to characterize the molecular mechanisms of multimorbidity of asthma, eczema and 
rhinitis. As a first step, proteins associated to either disease were identified using data mining 
approaches, and their overlap was calculated. Secondly, the functional interaction network was built, 
allowing the identification of cellular pathways involved in allergic multimorbidity. Finally, a 
network-based algorithm generated a ranked list of newly predicted multimorbidity-associated 
proteins (Aguilar, submitted). 
 
3- Novel findings  
3-1- Literature review on phenotypes and course of allergic diseases in children  
A large heterogeneity of allergic phenotypes exists and no systematic review had been carried out on 
phenotype classification or multimorbidity. MEDLINE was searched up to December 2012 to identify 
relevant original studies in children. From a total of 13,767 citations, 197 met the criteria for inclusion, 
of which 54% were cohorts. The review showed that studies reporting the phenotypes of IgE-
associated diseases in children are heterogeneous and often lack objective measures, making the expert 
panel phenotype definitions applied in MeDALL the largest consistent classification dataset currently 
existing. The knowledge on multimorbidity was mostly restricted to links between asthma and rhinitis 
(38).  
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3-2- Classical and novel phenotypes reveal the importance of multimorbidity  
The term multimorbidity is more appropriate than comorbidity since the primary allergic disease is 
poorly known and the allergy march accounts for few patients (39). Although the concept of 
multimorbidity of allergic diseases has been known for years (40), MeDALL is the first population 
study to have assessed allergic multimorbidity of allergic diseases using the dual approach: 
hypothesis-driven (41) and data-driven (unsupervised cluster analyses) (42), and to have quantified the 
net excess of multimorbidity  (41).   
Classical epidemiological methods enabled a precise analysis of multimorbidity of asthma, rhinitis and 
eczema (41). The absolute excess of any multimorbidity was 1·6%  for children aged 4 years and 
2·2% for children aged 8 years; 44% of the observed multimorbidity at age 4 years and 50·0%  at age 
8 years was not a result of chance. Children with multimorbidities at 4 years had an increased risk of 
having multimorbidity at 8 years. The coexistence of eczema, rhinitis and asthma in the same child is 
more common than expected by chance alone, suggesting that these diseases share causal mechanisms. 
For children without multimorbidity at 4 years, 38% of the multimorbidity at age 8 years was 
attributable to the presence of IgE sensitisation at age 4 years. On the other hand, the use of machine 
learning methods (42) showed that 30 to 40 %  of children at the age of 4 to 8 years belong to a 
multimorbidity cluster. This cluster included 99% of children exhibiting multimorbidity with classical 
models. Although IgE sensitisation is independently associated with excess multimorbidy, its presence 
at 4 years accounted for only 38% of the new multimorbidity at the age of 8 years, suggesting that IgE 
sensitisation can no longer be considered the common causal mechanism of multimorbidity for these 
diseases (Figure 1).  
 
Figure 1: Prevalence* of symptoms of asthma, rhinitis and eczema according to the 2 groups 
identified in cluster analysis, at 4 and 8 years (Garcia-Aymerich et al (42)) 
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3-3- Mono and polysensitisation distinct allergy phenotypes  
The concept of mono and polysensitization has been previously proposed (43-45) but never formally 
evaluated due to the lack of samples in a population-based study and inadequate methods making it 
impossible to study a wide array of allergens. This became possible in MeDALL. In the BAMSE 
cohort (Sweden), the same 2,607 children were tested at least twice at 4, 8 and 16 years (46). Results 
confirm that mono and polysensitisation represent two different phenotypes of IgE-associated 
diseases. These results were also confirmed in the MeDALL cohorts (2) and in patient cohorts in 
children (47). In the EGEA study, the mono and polysensitized MeDALL phenotypes (2) were 
confirmed in adults (48).   
 
3-4- Effect of pollutants in the development of allergic diseases 
Traffic-related air pollution (nitrogen dioxide (NO2), particulate matter < 2.5 µm (PM2.5), < 10 µm 
(PM10), and PM2.5 absorbance (“soot”)) was studied. For four cohorts, residential exposure to traffic-
related air pollution at the birth address and follow-up addresses was examined (10, 49, 50). Exposure 
to nitrogen dioxide (NO2) and PM2.5 absorbance early in life is a risk factor for the development of 
asthma through childhood and adolescence, particularly after the age of 4 years (49). Analyses of other 
environmental risk factors for allergy-related disease (e.g. second hand tobacco smoke, molds, 
dampness) are ongoing. 
 
3-5-  Gender switch during puberty 
Longitudinal gender-specific analyses of 18,852 children participating in PIAMA, BAMSE, 
LISAplus, GINIplus, DARC and MAS showed considerable changes in the sex-specific occurrence of 
asthma and allergic rhinitis at around puberty. The strong male predominance of asthma or rhinitis 
prevalence in pre-pubertal childhood declined as the teenagers grew older (manuscripts in 
preparation). Our hypothesis that by adulthood the gender imbalance in the prevalence is switching to 
a clear female predominance of asthma and rhinitis will be examined with the next follow-up data of 
MeDALL cohorts in adulthood. 
 
3-6- Omic data for allergy molecular fingerprints and phenotype handprints 
In the discovery phase of targeted proteomic, levels of a large panel of proteins via multiplexing and 
ELISAs were measured from four cohorts. In the replication phase, top biomarkers of interest were 
measured in seven cohorts. The analyses identified a potential novel biomarker of asthma and the role 
of systemic inflammation in multimorbidities in early childhood. Results were consistent using the 
classical and novel phenotypes (manuscript in preparation).  Following a hypothesis-driven approach, 
MeDALL data for CC16 (club cell secretory protein) were included in a large international 
collaborative study. Low CC16 levels at age 4 years predicted subsequent FEV1 deficits up to age 16 
in the BAMSE cohort and these data were in line with independent results from the CRS (USA) and 
MAAS (UK) cohorts (50). 
 
An epigenome wide association study on asthma was completed and followed up by a large replication 
study across all MeDALL cohorts (Xu et al, 2016, in preparation). Based on an a priory hypothesis, 
strong and consistent effects of maternal smoking on the child’s whole blood DNA methylome at age 
0, 4/5 and 8 years were observed and results published as part of the PACE consortium (Joubert et al, 
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submitted).  Moreover, the effects of traffic-related air pollution on DNA methylation have been 
investigated (Gruzieva et al, 2016, in preparation). 
Expression profiling of the identified genes is currently ongoing in these projects, based on the 
transcriptomic profiling elaborated at single- and multi-cohort levels, for single disease phenotypes 
and multimorbidities. An exhaustive portfolio of significant and statistically-validated genes, 
molecular interactions and pathways is available. A set of overlapping genes defines molecular 
fingerprints related to asthma, rhinitis and eczema, blood cell activity, immune and antigen response 
and receptor activity (Lemonnier et al., in preparation).  
In comprehensive integrative analyses, protein levels were analysed in relation to both genetic 
variation and methylation profiles in their encoding genes. Multiple CpG sites from 25 genes were 
found for possible mediation of effects of genetic variation on protein levels. By identifying a set of 
putatively functional SNPs and CpG methylation sites, these results may provide specific loci to be 
investigated in association studies. A focused integrated analysis in childhood asthma was completed 
with genetic-epigenetic-protein data for the asthma biomarker Chitinase-3-like protein 1 
(CHI3L1/YKL-40) showing that CHI3L1 genetic variation affects circulating YKL-40 by regulating 
its gene methylation profiles (Guerra S et al. in preparation).     
 
3-8- Mechanistic experimental studies in animal studies and in vitro to complement 
MeDALL data 
 A major achievement has been the construction of transgenic mice in which the TCR reacts to the 
relevant Der p 1 allergen of house dust mite (HDM).  A fine mapping of the T-cell response to HDM 
in vivo was possible.  This was achieved by performing the microarray analysis of CD4 T-cells 
obtained from these TCR transgenic mice, essentially unravelling a novel IL21 producing T-cell 
subset involved in asthma development (51). We also validated the effect of farm exposure on the 
development of allergy and asthma.  Mice exposed to farm dust fail to mount  allergy and asthma to 
HDM due to a down-regulation of epithelial cell activation and subsequent lack of dendritic cell 
activation.  The pathway involved the ubiquitin modifying enzyme A20.  Genetic polymorphisms of 
A20 were associated with the risk of developing asthma in a cohort study of children in rural Germany 
(52).  The latter study also involved innovative air liquid interface cultures of epithelial cells obtained 
by bronchoscopy.  In air liquid interface cultures of asthmatics, A20 levels were reduced compared 
with healthy controls. 
In allergic patients, the immune profile of the tonsils represents the atopic status of patients, with low 
expression of Th1. Cellular and molecular mechanisms of tolerance induction to food and 
aeroallergens occur in human tonsils, suggesting that they represent a suitable lymphatic organ for 
direct immune interventions (53-55). In addition to Treg cells, IL-10-producing regulatory B-cells 
have been demonstrated with a potent anti-inflammatory activity.  
Cytokine-producing memory B-cell subsets exist in humans and may show different pro-
inflammatory, anti-inflammatory as well as immune effector and immune regulatory functions. We 
identified novel molecules that play a role in B-cell regulation and demonstrate that functional human 
B-cell subsets show in vivo clonal expansion during allergen-tolerance, such as allergen 
immunotherapy and high-dose allergen exposure (56, 57). Moreover, Treg cells are reduced during 
asthma exacerbations as markers of virus-induced asthma exacerbations, which are of great interest for 
the development of future biomarkers (58). To better analyse cytokine producing immune cell subsets, 
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we developed an assay that allows the purification of any single and several cytokine secreting cell 
subsets as well as their characterization (59). 
The bronchial epithelial layer serves as the first site of exposure to inhaled allergens, dust particles, 
pollutants, or microorganisms. Consequently, bronchial epithelial cells are at the forefront of tissue 
defense and the innate immune response, preventing the invasion of tissues as a physical barrier. Tight 
junctions (TJs), located at the most apical region of the lateral cell membrane, seal the epithelium and 
form an essential part of the barrier between inner tissues and the external environment. They can be 
regulated by cytokines of the allergy pathways (60, 61). Many efforts have been made to improve the 
barrier integrity and it was recently demonstrated in vitro that the administration of CpG-DNA could 
be useful for restoring impaired epithelial barriers (62). 
 
4- Novel classification of allergic diseases: The MeDALL hypothesis (2)   
IgE sensitisation should be considered as a qualitative (IgE response) and quantitative trait (mono and 
polysensitization), as important clinical and immunological differences exist between mono and 
polysensitized subjects (Table 3). The integration of multimorbidities and polysensitization has 
resulted in a new classification framework of allergic diseases (2, 47) which could help to improve the 
understanding of genetic and epigenetic mechanisms of allergy and better manage allergic diseases 
(Tables 4 and 5).   
Table 3: Differences between mono and polysensitized subjects 
Polysensitization, as compared to non-sensitization and monosensitization, is associated with (2): 
• A higher frequency of family history of allergy (asthma and rhinitis) (63). 
• A higher prevalence of asthma and rhinitis symptoms. 
• A higher prevalence of multimorbidity. 
• A higher level of specific IgE and a higher level of total IgE compared to mono-sensitized. 
• A broader sensitization to different allergens.  
• The persistence of allergic diseases with a lower probability of remission of IgE sensitization and clinical 
allergy. 
 
Table 4: Novel classification of IgE-mediated diseases (2) 
1- Non-sensitized asymptomatic individuals 
2- IgE response restricted to one environmental allergen with no family history: low IgE responders (number 
of components and level of IgE) 
 Non-symptomatic subjects who are unlikely to develop symptoms over time. 
 Symptomatic subjects (symptoms similar to polysensitized subjects)  
3- Polyclonal IgE response to environmental allergens with family history: high IgE responders Most subjects 
are symptomatic, with an early life onset, a high rate of multimorbidities and persistence of the disease 
over time. 
4- Non-allergic polyclonal IgE without family history: Late-onset disease and local polyclonal IgE  
5- Intermediate phenotypes 
 Polyclonal IgE response without family history. The role of co-factors (pollutants, viruses) needs to be 
better understood. 
 IgE response restricted to few allergens. 
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Table 5: Implications of the novel definition of IgE-associated allergic diseases (2) 
Subphenotyping of allergic diseases for precision medicine: Phenotyping subtypes can be used to characterize 
allergic diseases, severity and progression, and may help identify unique targets for prevention and treatment.   
Clinical practice: An updated definition provides a framework to inform decisions relating to treatment 
priorities and to indicate need for improvement in health care and delivery through better organisation for 
prediction, diagnosis and treatment. The prediction of allergic disease trajectories in preschool children is 
essential. 
Clinical trials: Clarity on definitions is essential for clinical trials, evaluating efficacy and safety. The 
stratification of patients by sensitization and multimorbidity is essential in allergen immunotherapy (both for 
treatment and prevention).  
Research on mechanisms and genetics: The new definition is likely to change the concepts of the mechanisms 
of allergic disease and to propose novel mechanisms related to shared and unique genetic factors (64-66).  
Population studies: In longitudinal epidemiological population studies, standardised definitions are required to 
be able to compare cohorts across time and place and to develop dynamic models capturing risk factors which 
predict transitions through different stages of health.   
Public health planning: For public health purposes, a comprehensive definition is needed (i) to identify the 
prevalence, burden and costs incurred by all phenotypes; (ii) to improve quality of care and optimise health 
care planning and policies; and (iii) to model the economic and social benefits of population level preventive 
policies to improve respiratory health of the current generation of children and thus of future generations.  
Social welfare planning: For social welfare purposes, a phenotypic definition is also needed to predict the 
burden and costs at an early age in order to model the individual and collective economic and social benefits of 
specific interventions. 
Applicability to high and low-income countries: A uniform allergy definition should be applicable to the local 
and geographical conditions of all countries, phenotypes, risk factors, availability and affordability to treatment 
differing widely around the world. This would help to better understand which preventive measures are most 
effective in specific environments and interactions with parasitic diseases in particular. 
Development of novel preventive approaches and therapies: Detailed cellular and molecular phenotyping is 
needed to identify novel primary and secondary prevention strategies, as well as new targets for the 
development of novel therapies. Ultimately, novel therapies studied in clinical trials should help define IgE-
mediated pathways and determine the importance of the intervention in large patient populations or in sub-
populations of patients based on the concept of distinct phenotypes. The life course approach of allergic 
diseases is of great interest since it may lead to preventive strategies for health promotion and preventive 
policy measures. 
5- Clinical impact  
Many MeDALL data have been translated into clinical practice, and a meeting at the European 
Parliament was organised by EFA (European Federation of Allergy and Airways Diseases patient’s 
association) to conclude the project (May 27, 2015).  In particular, MeDALL results have an impact 
on precision medicine as they improve the stratification of allergic preschool children for diagnosis, 
prognosis, and allergen-specific immunotherapy. Multimorbidity and/or IgE polysensitisation are 
markers of persistence of disease.  
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5-1- Childhood asthma prediction models 
Early identification of children at risk of developing asthma at school age is crucial, but the usefulness 
of childhood asthma prediction models in clinical practice is still unclear. We systematically reviewed 
all existing prediction models to identify preschool children with asthma-like symptoms at risk of 
developing asthma at school age. Some models were able to better predict asthma development and 
others to better rule out asthma development. However, the predictive performance in both aspects 
simultaneously stood out in neither of the models. This study suggests that the prediction of asthma 
development is difficult (67), possibly because of interactions with viral infections.   
 
5-2- Prediction of the persistence of allergic diseases at 4 years   
Polysensitisation and/or multimorbidity at 4 years predicts the persistence of allergy later in life (36, 
37, 41). This result is of importance for the parents of affected children counselling counselling???: 
“Will my child grow out of his/her allergy?” is the invariable question raised by the parents. 
Polysensitisation to the major birch pollen allergen in combination with allergens of the same protein 
family predicted future birch pollen allergy much better than IgE to the birch pollen allergen extract 
itself. The same was true for polysensitisation to different cat and dog allergens in relation to the 
development of cat and dog allergy, respectively. The MeDALL results are the first that may propose 
a simple answer to the practicing physician if the results are confirmed elsewhere.  
5-3- Stratification of patients for the initiation of allergen-specific immunotherapy 
The results of the MeDALL (mono-polysensitization, multimorbidity) study, the systematic review on 
prediction models as well as recent studies in allergic rhinitis patients (68) and in the EGEA cohort 
(48) may help to propose a stratification of patients for treatment and future randomized control trials 
(69). Moreover, the molecular sensitization profiles determined with the MeDALL chip may be the 
basis for stratification for allergen-specific immunotherapy (69). 
5-4- Patient empowerment  
The goal and rationale of patient involvement in medical decisions is patient empowerment. 
Empowered patients know their disease. Since its inception, MeDALL has worked for and with the 
patients for their empowerment in the project. EFA, one of the MeDALL partners, was present at the 
beginning and end of the project.  
6- Ethics   
A specific WP was dedicated to ethics in MeDALL to manage ethical issues throughout the project. In 
addition, the Ethics WP prepared practical information on regulatory issues for exchanging biological 
samples and attached data for the relevant partners of MeDALL. This was made available as a 
practical web-based tool, as a complementary development of the site hSERN.eu developed by 
GA²LEN (70, 71). The conditions for exchanges of samples and data regarding a few countries 
(www.hsern.eu) were integrated online on the hSERN website. The communication of results and 
disclosure of incidental findings in longitudinal paediatric research have been innovative MeDALL 
initiatives (72). 
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7- MeDALL at the cross-road of the EU and WHO political agenda 
7-1- European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) and 
WHO  
The NCD WHO research agenda indicated that birth cohorts were needed for the understanding of the 
early determinants of chronic respiratory diseases for innovative health promotion strategies (73). 
MeDALL is in line with this agenda.  
The WHO Global Alliance against Chronic Respiratory Diseases (GARD) action plan (74-76) was the 
model of AIRWAYS ICPs (Integrated care pathways for airway diseases) (77-79), a new initiative of 
the EIP on AHA. This was jointly organised by MeDALL, the Reference Site Network of the EIP on 
AHA (DG Santé and DG Connect) (80), and WHO GARD (Figure 2).   
Figure 2: MeDALL interactions between EU and WHO (from (78)) 
 
GARD: Global Alliance against Chronic Respiratory Diseases, NGO: nongovernmental organisation, GO: Governmental 
organisation, MOH: Ministry of Health, NCD: noncommunicable disease. 
MeDALL has interacted with the EIP on AHA (80-82) via several actions. Synergies have been 
achieved between MeDALL and AIRWAYS ICPs - the model of chronic diseases of Area 5 of the B3 
Action Plan of the EIP on AHA (77) - due to their burden, mortality and co-morbidities (75) as well as 
their early development (83, 84). AIRWAYS ICPs has strategic relevance to the European Union 
Health Strategy, adding value to existing public health knowledge.  
 
7-2- Impact of MeDALL on the EU policies in the early diagnosis and management of 
allergic diseases in active and healthy ageing 
The leading priority for the Polish Presidency of the Council of the European Union (2011) was to 
reduce health inequalities across European societies, and, within its framework, to concentrate on the 
prevention and control of respiratory diseases in children in order to promote AHA (83, 84). The 
clinical implications of MeDALL reinforce the priority of the EU and suggest solutions for 
implementation. 
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Pre-and peri-natal events play a fundamental role in health, the development of diseases and ageing 
(83, 84). The developmental determinants of NCDs in ageing were reinforced during the Cyprus 
Presidency of the EU Council (2012) (85). A meeting was convened by the Reference Site of 
Languedoc Roussillon (80) on the early determinants of active and healthy ageing (NIH, EIP on AHA, 
MeDALL) (86). These concepts have been considered in the senioral policy of Poland (87).  
Moreover, the project results were presented on the 28th of May 2015 at the European Parliament in 
Brussels to an audience composed of policy makers, healthcare professionals, researchers and patients’ 
representatives.  
 
7-3- Translation into policies   
The first results of "The Finnish Allergy Programme 2008-2018" (88), supported by MeDALL data, 
indicate that allergy burden can be reduced with relatively simple means. This has been endorsed by 
the Norwegian Allergy Health Programme and, along with the Finnish programme, will serve as a 
platform for other countries (Oslo, November 2014) (89). 
 
8- Gaps and the future 
The European Commission considers MeDALL to be a success story. A summary can be found on the 
Horizon 2020 website.  It will also be present in the future Health Success Stories Brochure, scheduled 
to be launched within the next few months. 
As other similar projects, MeDALL has involved a huge multidisciplinary effort by a large 
international network of partners. MeDALL has been possible thanks to previous consortiums (such as 
GA
2
LEN, ENRIECO and CHICOS) (12) that have paved the way of pooling and integrating national 
or local birth cohorts. Each of these consortiums has experienced the challenge of sustaining the 
network. MeDALL includes over 44,000 children recruited at birth for the  study of the most common 
chronic disease (allergy). The power of the study is sufficient for the assessment of primary diseases 
(asthma, rhinitis and eczema) but it is at the limit for multimorbidity, in particular at the early stages of 
the disease (4 years) (41) and for the discovery of biomarkers. In studies of multimorbid NCDs (e.g. 
COPD, cardiovascular diseases, diabetes….), the power of population cohorts will be sufficient to 
assess established diseases. However, cohorts are likely to fail in the identification of early 
multimorbid diseases, their causality and discovery of biomarkers. Thus, the data of MeDALL are 
generalizable to multimorbid NCDs across the life cycle. Funding from the EU Structure and 
Cohesion Funds have been obtained by the Région Languedoc Roussillon in the frame of MACVIA-
LR (80, 82) to maintain the database until new funding from EU or other sources is available for other 
projects.   
 
Despite the successful experience of MeDALL to integrate birth cohorts of asthma and allergy, we 
really do need to escalate the level of integration. A new methodology should be proposed to combine 
the strengths and weaknesses of the birth cohorts, possibly enriching them with patient cohorts (47, 
90, 91), registered data in primary care (92), clinical trial databases (93) and/or internet-based studies. 
In very young children, similar severe asthma phenotypes exist in patient cohorts of persistent 
recurrent wheezers (90) and in cohorts in the general population (94), suggesting the possibility of 
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pooling both types of cohorts. However, ethical issues are of great importance in pooling such studies.  
 
Developing a systems medicine approach to complex diseases is a phenomenal challenge. MeDALL 
was used as a model of systems medicine and has initiated a common language for the assessment of 
all non-communicable diseases (95). The novel trend for the management of NCDs is evolving 
towards integrative, holistic approaches. NCDs are intertwined with ageing. To tackle NCDs in their 
totality in order to reduce their burden and societal impact, it has been proposed that NCDs should be 
considered as a single expression of disease with different risk factors and entities. An innovative 
integrated health system built around systems medicine and strategic partnerships is proposed to 
combat NCDs (4, 95).  
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